Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Payables: 2015-2025

Historic Payables for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $1.7 million.

  • Assembly Biosciences' Payables rose 26.07% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 16.91%. This contributed to the annual value of $585,000 for FY2024, which is 26.90% up from last year.
  • Assembly Biosciences' Payables amounted to $1.7 million in Q3 2025, which was up 126.51% from $743,000 recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Payables registered a high of $3.6 million during Q1 2021, and its lowest value of $461,000 during Q4 2023.
  • For the 3-year period, Assembly Biosciences' Payables averaged around $917,818, with its median value being $801,000 (2024).
  • As far as peak fluctuations go, Assembly Biosciences' Payables tumbled by 81.51% in 2023, and later soared by 76.12% in 2024.
  • Over the past 5 years, Assembly Biosciences' Payables (Quarterly) stood at $2.7 million in 2021, then decreased by 6.24% to $2.5 million in 2022, then slumped by 81.51% to $461,000 in 2023, then climbed by 26.90% to $585,000 in 2024, then rose by 26.07% to $1.7 million in 2025.
  • Its Payables was $1.7 million in Q3 2025, compared to $743,000 in Q2 2025 and $875,000 in Q1 2025.